Grifols GRFS
NASDAQ GRFS
$7.99 +0.00 (+0.00%)
As of: Aug 21, 2026 · 3:59 PM EDT

Grifols (GRFS) Other Non-Current Liabilities (2009 - 2025)

Grifols' (GRFS) quarterly Other Non-Current Liabilities came in at $138.5 million in Q4 2025, up 3.7% YoY from $133.6 million in Q4 2024, and up 3.7% on a QoQ basis from $133.6 million in Q4 2024.

Grifols (GRFS) Other Non-Current Liabilities (2009 - 2025) Analysis & Trends

Grifols (GRFS) has 17 years of Other Non-Current Liabilities data on file, last reported at $138.5 million in Q4 2025.

  • Quarterly Other Non-Current Liabilities rose 3.7% year-over-year to $138.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $138.5 million (up 3.7% YoY) and the FY2025 annual result came in at $138.5 million, up 3.7% from the prior year.
  • Other Non-Current Liabilities improved to $138.5 million in Q4 2025, from $133.6 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $138.5 million in Q4 2025 to a low of $17.2 million in Q4 2021.
  • A 5-year average of $105.5 million and a median of $125.8 million in 2023 frame the typical range for Other Non-Current Liabilities.
  • Annual changes were most pronounced in 2021 — Other Non-Current Liabilities dropped 11.98% — and 2022, when it surged 552.83%.
  • Tracing GRFS's Other Non-Current Liabilities over 5 years: stood at $17.2 million in 2021, then soared by 552.83% to $112.3 million in 2022, then advanced by 12.03% to $125.8 million in 2023, then increased by 6.18% to $133.6 million in 2024, then grew by 3.7% to $138.5 million in 2025.
  • The last three Other Non-Current Liabilities figures came in at $138.5 million (Q4 2025), $133.6 million (Q4 2024), and $125.8 million (Q4 2023), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 652.20 Bn 631.44 Bn 17.26 Bn
2 AbbVie 469.51 Bn 462.94 Bn 12.70 Bn
3 Merck 376.81 Bn 369.67 Bn 12.21 Bn
4 Novartis Ag 303.04 Bn 295.35 Bn 11.24 Bn
5 Astrazeneca 257.61 Bn 252.71 Bn 12.86 Bn
6 Amgen 237.37 Bn 223.38 Bn 7.24 Bn
7 Gilead Sciences 181.73 Bn 178.55 Bn 6.22 Bn
8 Pfizer 159.66 Bn 147.96 Bn 10.94 Bn
9 Gsk 106.24 Bn 102.07 Bn 8.24 Bn
10 Grifols 5.45 Bn 4.45 Bn -

Historic Data

Download Data
DateValue
Dec 31, 2025 138.52 Mn
Dec 31, 2024 133.57 Mn
Dec 31, 2023 125.80 Mn
Dec 31, 2022 112.29 Mn
Dec 31, 2021 17.20 Mn
Dec 31, 2020 19.54 Mn
Sep 30, 2020 661.48 Mn
Mar 31, 2020 543.55 Mn
Dec 31, 2019 8.89 Mn
Sep 30, 2019 497.08 Mn
Dec 31, 2018 6.98 Mn
Sep 30, 2018 500.18 Mn
Jun 30, 2018 96.90 Mn
Mar 31, 2018 529.17 Mn
Dec 31, 2017 6.79 Mn
Jun 30, 2017 85.29 Mn
Dec 31, 2016 5.53 Mn
Sep 30, 2016 97.13 Mn
Jun 30, 2016 132.34 Mn
Dec 31, 2015 5.46 Mn